Research only
All of
ALZ.ORG Research Center Alzheimer's Association International Conference ISTAART Journal Grants TrialMatch Press Donate Contact

Scientific Sessions

The schedule below reflects the invited program.

Registered attendees: To search a full listing of sessions, view abstracts and plan your schedule for AAIC on your desktop, please use the content portal.

Non-registrants: View and search a full listing of sessions available at AAIC 2014 (abstracts excluded).



SUNDAY, JULY 13: 10:45 - 11:45 a.m.

Bruno Vellas
Update on Preclinical and Prevention Trials in Alzheimer's Disease
Session: PL-01-01*

*Presented after the Association Welcome Ceremony.



MONDAY, JULY 14: 10:30 - 11:45 a.m.

Francine Grodstein
United States
Nutrition and Prevention

Wiesje Van der Flier
Predicting Clinical Progression in Subjective Cognitive Decline
Session: PL-02-02



TUESDAY, JULY 15: 10:30 - 11:45 a.m.

Kenneth Langa
United States
Is the Risk of Alzheimer's Disease Declining? A Review of Evidence From Around the World
Session: PL-03-01

Kári Stefánsson
Inge Grundke-Iqbal Lecture for Alzheimer's Research: Four Anecdotes on the Genetics of Alzheimer‘s Disease
Session: PL-03-02



WEDNESDAY, JULY 15: 10:45 - 11:45 a.m.

Rosa Rademakers
United States
Update on C9ORF72 Research in FTLD and ALS
Session: PL-04-01

Brad Boeve
United States
Complexities of Lewy Body Disease
Session: PL-04-02



THURSDAY, JULY 17: 10:15 - 11:15 a.m.

Colin Masters
How to Change and Monitor the Rates of Aβ Amyloid Accumulation and Cognitive Decline in Alzheimer's Disease
Session: PL-05-01

Randall Bateman
United States
Human Metabolism and Kinetics of Alzheimer's Disease Proteins
Session: PL-05-02






SUNDAY, JULY 13: 8:30 - 10 a.m.

Is It Only Alzheimer's Disease, and Is That Important?

Session: S1-01
Theme: Diagnosis and Prognosis
Topic: Neuropathology




Pathology Underlying Regional Brain Atrophy (S1-01-01)

Deniz Erten-Lyons
Portland VA Medical Center,
United States

Hippocampal Sclerosis of Aging (S1-01-02)

Julie Schneider
Rush University Alzheimer's Disease Center,
United States

Cerebral Amyloid Angiopathy and Alzheimer's Disease (S1-01-03)

Steve Greenberg
Massachusetts General Hospital,
United States

Overlapping Proteinopathies in the Elderly and Their Significance (S1-01-04)

Gabor Kovacs
University of Vienna, Austria



Non-Amyloid Based Therapies

Session: S1-02
Theme: Therapeutics
Topic: Clinical and Preclinical




M1 Muscarinic Agonists and a Multipotent Activator of Sigma1/M1 Muscarinic Receptors: Future Therapeutics of Alzheimer's Disease (S1-02-01

To be announced.

Lu AE58054, a 5-HT6 Antagonist for Alzheimer's Disease (S1-02-02)

Eskild Colding-Jørgensen
Lundbeck Research DK,

NACHR7 Agonist for Alzheimer's Disease (S1-02-03)

Gerhard Koenig
Envivo Pharmaceuticals, United States

Tau Immunotherapies (S1-02-04)

Einar Sigurdsson
New York University, United States



MONDAY, JULY 14: 8:30 - 10 a.m.

Long-Term Care: Best Practices for Patients With Dementia

Session: S2-01
Theme: Public Health and Psychosocial
Topic: Psychosocial and Environmental




How to Implement Clinical Research in Nursing Homes? (S2-01-01)

Bob Woods
Bangor University, United Kingdom

What Is Evidence for Effective Long-Term Practices? (S2-01-02)

Lynn Chenoweth
University of New South Wales, Australia

How to Optimize Care Plans for Patients in Long-Term Care (S2-01-03)

John Morley
St. Louis University of Medicine, United States

Effective and Ineffective Treatments in Long-Term Care (S2-01-04)

Jiska Cohen-Mansfield
Tel-Aviv University, Israel



Shared Genetic Risks for Neurodegeneration Across Diseases

Session: S2-02
Theme: Basic and Translational Science
Topic: Genetics




Insights into the ALS-FTD Continuum From the Study of C9orf72 (S2-02-01)

Bryan Traynor
National Institutes on Aging, United States

Phagocytosis Pathway of Microglia Linked to Neurodegeneration (S2-02-02)

Harald Neumann
University of Bonn, Germany

Lrrk2 and Parkinson's Disease (S2-02-03)

Andrew Singleton
National Institutes on Aging, United States

Mechanisms of Tau Haplotype Effects on Disease (S2-02-04)

Richard Wade-Martins
Oxford Parkinson's Disease Centre, United Kingdom

TUESDAY, JULY 15: 8:30 - 10 a.m.

Does Dementia Screening Lead to Overdiagnosis or an Opportunity for Early Intervention?

Session: S3-01
Theme: Public Health and Psychosocial
Topic: Health Economics and Policy




Screening for Alzheimer Disease in Cognitively Normal Older Adults: Subjective Cognitive Decline vs Informant Report (S3-01-01)

John Morris
Washington University, United States

Screening for Alzheimer's Disease: Why and How? (S3-01-02)

Bruno Dubois
Salpêtrière University Hospital, France

Early Detection of Dementia and the Principles of Screening (S3-01-03)

Carol Brayne
University of Cambridge, United Kingdom

Impact of Memory Testing in Different Care Settings in Mislabelling of Dementia (S3-01-04)

Larry Chambers
Alzheimer Society Canada, Canada



Clinical Trials and Frontotemporal Lobar Dementia (FTLD)

Session: S3-02
Theme: Therapeutics
Topic: Clinical




Convergence of Cell Autonomous and Non-autonomous Stress Systems on Tau Pathogenesis (S3-02-01)

Chad Dickey
University of San Francisco, United States

Antisense Oligonucleotides as Therapeutic Agents (S3-02-02)

Tim Miller
Washington University, United States

Therapies That Enhance Progranulin Expression (S3-02-03)

Joachim Herz
University of Texas, United States

Mechanisms of Toxicity and Therapeutic Approaches for c9FTD/ALS (S3-02-04)

Leonard Petrucelli
Mayo Clinic, United States



WEDNESDAY, JULY 16: 8:30 - 10 a.m.

Standardization of Biomarkers for Use in Clinical Practice

Session: S4-01
Theme: Diagnosis and Prognosis
Topic: Biomarkers




Hippocampal Volume (S4-01-01)

Giovanni Frisoni
IRCCS Fatebenefretelli, Italy

Standardization of Amyloid PET: The Centiloid Project (S4-01-02)

William Klunk
University of Pittsburgh, United States

Fluorodeoxyglucose (18F) PET (S4-01-03)

Satoshi Minoshima
University of Washington, United States

Cerebrospinal Fluid (S4-01-04)

Charlotte Teunissen
VU University Medical Center, Netherlands



Role of Immune Response/Microglia in Alzheimer's Disease Risk

Session: S4-02
Theme: Basic and Translational Science
Topic: Molecular and Cell Biology




Innate Immunity and Regulation of Abeta (S4-02-01)

Michael Heneka
University of Bonn, Germany

Harnessing Innate Immunity to Treat Alzheimer's Disease (S4-02-02)

Terrence Town
University of Southern California, United States

Complement in Alzheimer's Disease: Lessons From C3-Deficient Mice (S4-02-03)

Cynthia Lemere
Brigham and Women's Hospital, United States

Microglial Phenotypes and Aging in Alzheimer's Disease and Other Neurodegenerative Diseases (S4-02-04)

Joseph El Khoury
Massachusetts General Hospital, United States



Access 2014 program content

Searchable program content, including session topics, speakers and abstracts, is now available.

Where the world reveals the latest dementia research • Washington, D.C., United States • July 18-23, 2015